AR128353A1 - Síntesis de un inhibidor de kif18a - Google Patents

Síntesis de un inhibidor de kif18a

Info

Publication number
AR128353A1
AR128353A1 ARP230100178A ARP230100178A AR128353A1 AR 128353 A1 AR128353 A1 AR 128353A1 AR P230100178 A ARP230100178 A AR P230100178A AR P230100178 A ARP230100178 A AR P230100178A AR 128353 A1 AR128353 A1 AR 128353A1
Authority
AR
Argentina
Prior art keywords
compound
kif18a
inhibitor
synthesis
salt
Prior art date
Application number
ARP230100178A
Other languages
English (en)
Spanish (es)
Inventor
Sebastien Caille
Daniel Gerard Greene
Michael Thomas Corbett
Carolyn Wei
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR128353A1 publication Critical patent/AR128353A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ARP230100178A 2022-01-26 2023-01-26 Síntesis de un inhibidor de kif18a AR128353A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263303470P 2022-01-26 2022-01-26

Publications (1)

Publication Number Publication Date
AR128353A1 true AR128353A1 (es) 2024-04-24

Family

ID=85328813

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100178A AR128353A1 (es) 2022-01-26 2023-01-26 Síntesis de un inhibidor de kif18a

Country Status (12)

Country Link
US (1) US20250129050A1 (cg-RX-API-DMAC10.html)
EP (1) EP4469437A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025505892A (cg-RX-API-DMAC10.html)
KR (1) KR20240144140A (cg-RX-API-DMAC10.html)
CN (1) CN118922406A (cg-RX-API-DMAC10.html)
AR (1) AR128353A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023211589A1 (cg-RX-API-DMAC10.html)
CA (1) CA3248925A1 (cg-RX-API-DMAC10.html)
IL (1) IL314221A (cg-RX-API-DMAC10.html)
MX (1) MX2024009163A (cg-RX-API-DMAC10.html)
TW (1) TW202342451A (cg-RX-API-DMAC10.html)
WO (1) WO2023146973A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
CR20250087A (es) 2022-08-18 2025-07-11 Accent Therapeutics Inc Inhibidores de kif18a y usos de estos
CN115925589A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钙盐及其制备方法
CN121693499A (zh) * 2023-08-16 2026-03-17 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283639B2 (en) * 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
JP2023521802A (ja) * 2020-04-14 2023-05-25 アムジエン・インコーポレーテツド 新生物疾患の処置のためのkif18a阻害剤

Also Published As

Publication number Publication date
CA3248925A1 (en) 2023-08-03
WO2023146973A1 (en) 2023-08-03
AU2023211589A1 (en) 2024-07-25
US20250129050A1 (en) 2025-04-24
KR20240144140A (ko) 2024-10-02
TW202342451A (zh) 2023-11-01
IL314221A (en) 2024-09-01
EP4469437A1 (en) 2024-12-04
JP2025505892A (ja) 2025-03-03
MX2024009163A (es) 2024-08-09
CN118922406A (zh) 2024-11-08

Similar Documents

Publication Publication Date Title
MX2024009163A (es) Sintesis de un inhibidor de kif18a.
CO2022012476A2 (es) Hidrato cristalino de un compuesto inhibidor de jak
PE20231938A1 (es) Inhibidores de cdk y metodos de uso de estos
CL2022001091A1 (es) Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco (divisional de solicitud 202001871).
AR111960A1 (es) Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
ES2052452B1 (es) Procedimiento de preparacion de inhibidores duales de no-sintasa y ciclooxigenasa.
CL2021000481A1 (es) Inhibidores de sarcómeros cardíacos.
DK1485359T3 (da) Natriumkanalblokkere
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
AR124694A1 (es) Hidrato cristalino de sal de sodio de topramezona novedoso y método de preparación del mismo
ECSP066968A (es) Compuestos de metil-aril o heteroaril-amida sustituida
CY1105899T1 (el) Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες
PE20242071A1 (es) Compuestos moduladores de diacilglicerol quinasa
TW200635585A (en) Monocyclic substituted methanones
CO2024013702A2 (es) Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3
CL2023001301A1 (es) 1,4-diazepanonas bicíclicas y sus usos terapéuticos.
AR129946A1 (es) Inhibidores de cbl-b y métodos de uso de los mismos
UY39898A (es) Un proceso para la preparación de piroxasulfona.
AR041861A1 (es) Feniliso (tio) cianatos, procesos e intermediarios para su preparacion.
ES2421447T3 (es) Métodos para proteger frente a apoptosis usando lipopéptidos
CO2023006912A2 (es) Nuevos derivados de indazol acetileno
CO2022012773A2 (es) Moduladores de nampt
DE60229054D1 (de) Synthese von zyklopentadien derivaten
CR20240173A (es) Compuestos de cd73